Annual CFO
-$163.28 M
-$48.38 M-42.11%
December 31, 2023
Summary
- As of February 7, 2025, NMRA annual cash flow from operations is -$163.28 million, with the most recent change of -$48.38 million (-42.11%) on December 31, 2023.
- During the last 3 years, NMRA annual CFO has fallen by -$136.52 million (-510.16%).
- NMRA annual CFO is now -510.16% below its all-time high of -$26.76 million, reached on December 1, 2020.
Performance
NMRA Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$33.48 M
+$22.68 M+40.38%
September 30, 2024
Summary
- As of February 7, 2025, NMRA quarterly cash flow from operations is -$33.48 million, with the most recent change of +$22.68 million (+40.38%) on September 30, 2024.
- Over the past year, NMRA quarterly CFO has increased by +$9.47 million (+22.05%).
- NMRA quarterly CFO is now -146.80% below its all-time high of -$13.57 million, reached on June 1, 2021.
Performance
NMRA Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$184.04 M
+$14.29 M+7.21%
September 30, 2024
Summary
- As of February 7, 2025, NMRA TTM cash flow from operations is -$184.04 million, with the most recent change of +$14.29 million (+7.21%) on September 30, 2024.
- Over the past year, NMRA TTM CFO has dropped by -$10.85 million (-6.26%).
- NMRA TTM CFO is now -1107.28% below its all-time high of -$15.24 million, reached on March 1, 2021.
Performance
NMRA TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
NMRA Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -42.1% | +22.1% | -6.3% |
| 3 y3 years | -510.2% | -26.0% | -74.7% |
| 5 y5 years | - | -26.0% | -74.7% |
NMRA Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -116.5% | at low | -30.0% | +40.4% | -144.0% | +7.2% |
| 5 y | 5-year | -510.2% | at low | -146.8% | +40.4% | -1107.3% | +7.2% |
| alltime | all time | -510.2% | at low | -146.8% | +40.4% | -1107.3% | +7.2% |
Neumora Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$33.48 M(-40.4%) | -$184.04 M(-7.2%) |
| Jun 2024 | - | -$56.16 M(+30.7%) | -$198.33 M(+14.5%) |
| Mar 2024 | - | -$42.95 M(-16.5%) | -$173.19 M(+6.1%) |
| Dec 2023 | -$163.28 M(+42.1%) | -$51.44 M(+7.7%) | -$163.28 M(+14.8%) |
| Sep 2023 | - | -$47.77 M(+54.0%) | -$142.20 M(+18.3%) |
| Jun 2023 | - | -$31.02 M(-6.1%) | -$120.19 M(+3.8%) |
| Mar 2023 | - | -$33.04 M(+8.8%) | -$115.75 M(+0.7%) |
| Dec 2022 | -$114.90 M | -$30.37 M(+17.9%) | -$114.90 M(+0.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2022 | - | -$25.76 M(-3.1%) | -$113.88 M(+8.1%) |
| Jun 2022 | - | -$26.58 M(-17.4%) | -$105.38 M(+14.1%) |
| Mar 2022 | - | -$32.19 M(+9.7%) | -$92.36 M(+22.5%) |
| Dec 2021 | -$75.42 M(+181.8%) | - | - |
| Dec 2021 | - | -$29.35 M(+70.1%) | -$75.42 M(+63.7%) |
| Sep 2021 | - | -$17.26 M(+27.2%) | -$46.07 M(+59.9%) |
| Jun 2021 | - | -$13.57 M(-11.0%) | -$28.81 M(+89.0%) |
| Mar 2021 | - | -$15.24 M | -$15.24 M |
| Dec 2020 | -$26.76 M | - | - |
FAQ
- What is Neumora Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Neumora Therapeutics?
- What is Neumora Therapeutics annual CFO year-on-year change?
- What is Neumora Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Neumora Therapeutics?
- What is Neumora Therapeutics quarterly CFO year-on-year change?
- What is Neumora Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Neumora Therapeutics?
- What is Neumora Therapeutics TTM CFO year-on-year change?
What is Neumora Therapeutics annual cash flow from operations?
The current annual CFO of NMRA is -$163.28 M
What is the all time high annual CFO for Neumora Therapeutics?
Neumora Therapeutics all-time high annual cash flow from operations is -$26.76 M
What is Neumora Therapeutics annual CFO year-on-year change?
Over the past year, NMRA annual cash flow from operations has changed by -$48.38 M (-42.11%)
What is Neumora Therapeutics quarterly cash flow from operations?
The current quarterly CFO of NMRA is -$33.48 M
What is the all time high quarterly CFO for Neumora Therapeutics?
Neumora Therapeutics all-time high quarterly cash flow from operations is -$13.57 M
What is Neumora Therapeutics quarterly CFO year-on-year change?
Over the past year, NMRA quarterly cash flow from operations has changed by +$9.47 M (+22.05%)
What is Neumora Therapeutics TTM cash flow from operations?
The current TTM CFO of NMRA is -$184.04 M
What is the all time high TTM CFO for Neumora Therapeutics?
Neumora Therapeutics all-time high TTM cash flow from operations is -$15.24 M
What is Neumora Therapeutics TTM CFO year-on-year change?
Over the past year, NMRA TTM cash flow from operations has changed by -$10.85 M (-6.26%)